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Backbone cyclization of analgesic conotoxin GeXIVA facilitates direct folding of
the ribbon isomer
Abstract
Conotoxin GeXIVA inhibits the α9α10 nicotinic acetylcholine receptor (nAChR) and is analgesic in animal
models of pain. α-Conotoxins have four cysteines that can have three possible disulfide connectivities:
globular (CysI-CysIII and CysII-CysIV), ribbon (CysI-CysIV and CysII-CysIII), or bead (CysI-CysII and
CysIII-CysIV). Native α-conotoxins preferably adopt the globular connectivity, and previous studies of αconotoxins have focused on the globular isomers as the ribbon and bead isomers typically have lower
potency at nAChRs than the globular form. A recent report showed that the bead and ribbon isomers of
GeXIVA are more potent than the globular isomer, with low nanomolar half-maximal inhibitory
concentrations (IC50). Despite this high potency, the therapeutic potential of GeXIVA is limited, because
like most peptides, it is susceptible to proteo-lytic degradation and is challenging to synthesize in high
yield. Here we used backbone cyclization as a strategy to improve the folding yield as well as increase the
serum stability of ribbon GeXIVA while preserving activity at the α9α10 nAChR. Specifically, cyclization of
ribbon GeXIVA with a two-residue linker maintained the biological activity at the human α9α10 nAChR and
improved stability in human serum. Short linkers led to selective formation of the ribbon disulfide isomer
without requiring orthogonal protection. Overall, this study highlights the value of backbone cyclization in
directing folding, improving yields, and stabilizing conotoxins with therapeutic potential.
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Acetylcholine receptors are present in the nervous system
and at neuromuscular junctions and are defined as either
muscarinic acetylcholine receptors or nicotinic acetylcholine receptors (nAChRs)2 (1, 2). Neuronal nAChR subtypes
are homo- or heteropentamers formed by the combination of
␣ (␣2–␣10) and ␤ (␤2–␤4) subunits. These neuronal nAChR
subtypes are involved in a range of conditions and diseases,
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including neuropathic pain, nicotine addiction, schizophrenia,
Parkinson’s disease, and Alzheimer’s disease (3, 4).
Conotoxins are disulfide-rich peptides found in the venoms
of marine cone snails that can selectively and potently alter the
function of ion channels and receptors of the nervous system
(5–7). Some have been used as pharmacological probes or
developed as drug leads (8, 9). One notable example is -conotoxin MVIIA (also called ziconotide or Prialt威), which targets
the calcium channel CaV2.2 and is an approved drug to treat
neuropathic pain (10, 11). Likewise, Vc1.1 reached phase II clinical trials for the treatment of neuropathic pain, and RgIA also
entered phase I trials. These latter two peptides have high
potency at the ␣9␣10 nAChR, which is considered a pain target,
although the full mechanism(s) of analgesia are not understood
(12, 13), and G protein-coupled receptors such as the GABAB
receptor have also been suggested as targets (14 –17).
The sequence of conotoxin GeXIVA was identified recently
in a transcriptome analysis of the venom duct of Conus generalis (18). This 28-amino acid peptide has four cysteines (Cys
I–IV) that can theoretically form three isomers depending on
the disulfide connections: globular (CysI–CysIII and CysII–
CysIV), ribbon (CysI–CysIV and CysII–CysIII), or bead (CysI–
CysII and CysIII–CysIV) as shown in Fig. 1. Surprisingly, all three
isomers of GeXIVA inhibit the rat ␣9␣10 nAChR with similar
potency, although the bead and ribbon isomers are slightly
more potent than the globular (IC50 of the bead ⫽ 4.6 nM; ribbon ⫽ 7.0 nM; and globular ⫽ 22.7 nM) (18). NMR structure
calculations have shown that ribbon GeXIVA is flexible while
still having a more defined structure than the other two isomers
(18). These isomers exhibit higher or similar potency at rat
␣9␣10 nAChR compared with Vc1.1 (19) or RgIA (20). In addition, the ribbon and bead isomers of GeXIVA showed promise
in relieving neuropathic pain in a chronic constriction injury
model and also in a tail-flick model of acute pain (21).
Peptides, including conotoxins, typically have low oral bioavailability and are easily degraded by proteases in vivo, thus
decreasing their therapeutic potential (22–24). Over the last
decade, cyclic peptides have been discovered in animals, plants,
fungi, and bacteria and offer clues toward improving the stability of peptides (25–27). Head-to-tail cyclic peptides are typically more resistant to thermal or enzymatic degradation than
their linear counterparts (28, 29). Improving the stability of
conotoxins in biological fluids using backbone cyclization was
initially inspired by research into naturally occurring cyclic
J. Biol. Chem. (2017) 292(41) 17101–17112
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Conotoxin GeXIVA inhibits the ␣9␣10 nicotinic acetylcholine receptor (nAChR) and is analgesic in animal models of pain.
␣-Conotoxins have four cysteines that can have three possible
disulfide connectivities: globular (CysI–CysIII and CysII–CysIV),
ribbon (CysI–CysIV and CysII–CysIII), or bead (CysI–CysII and
CysIII–CysIV). Native ␣-conotoxins preferably adopt the globular connectivity, and previous studies of ␣-conotoxins have
focused on the globular isomers as the ribbon and bead isomers
typically have lower potency at nAChRs than the globular form.
A recent report showed that the bead and ribbon isomers
of GeXIVA are more potent than the globular isomer, with
low nanomolar half-maximal inhibitory concentrations (IC50).
Despite this high potency, the therapeutic potential of GeXIVA
is limited, because like most peptides, it is susceptible to proteolytic degradation and is challenging to synthesize in high yield.
Here we used backbone cyclization as a strategy to improve the
folding yield as well as increase the serum stability of ribbon
GeXIVA while preserving activity at the ␣9␣10 nAChR. Specifically, cyclization of ribbon GeXIVA with a two-residue linker
maintained the biological activity at the human ␣9␣10 nAChR
and improved stability in human serum. Short linkers led to
selective formation of the ribbon disulfide isomer without
requiring orthogonal protection. Overall, this study highlights
the value of backbone cyclization in directing folding, improving yields, and stabilizing conotoxins with therapeutic potential.

Cyclization improves selective folding of conotoxin GeXIVA

Figure 1. The three isomers of ␣⌷-conotoxin GeXIVA and the 3D NMR solution structure of ribbon GeXIVA (18). Cys residues are labeled with Roman
numerals (I–IV), and the disulfide bonds are shown as yellow sticks. The structure shown for the ribbon GeXIVA is the lowest energy conformer from an ensemble
of 10 NMR models.

Results
Cyclic GeXIVA ribbon isomer retains native structure
NMR structure calculations for ribbon GeXIVA (18) showed
that its N and C termini are maintained in close proximity
(⬃6.4 Å) by a disulfide bridge between the first and last Cys
residues (Fig. 1). Five linkers were designed using molecular
modeling to bridge the termini, and all were geometrically
compatible with the linear peptide structure, with the cyclic
backbones maintained within 1 Å root-mean-square deviation
(RMSD) of the linear peptide. The data suggested that even a
one-residue linker is sufficient to cyclize the backbone of ribbon GeXIVA without perturbing structure. Models of cyclic
GeXIVA with minimum perturbation of the parent peptide
backbone are shown in Fig. 2. For experimental validation, we
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focused on three short linkers (G, GG, and GAG) and the three
corresponding cyclic variants: ribbon cGeXIVA_G, ribbon
cGeXIVA_GG, and ribbon cGeXIVA_GAG. The three isomers
of linear GeXIVA and the three cyclic ribbon analogs were synthesized using orthogonal protection of the cysteine side chains
to orient the folding toward a unique disulfide isomer. The
yields of three isomers of linear GeXIVA and cyclic ribbon
GeXIVA were low (⬍1%) using a two-step oxidation method.
Although we optimized the purification procedure, globular
GeXIVA could not be completely purified. We therefore explored an alternative one-pot synthetic approach.
One-pot oxidative folding
Non-directed oxidative folding of GeXIVA and cGeXIVA_
GG was carried out in NH4HCO3 (pH 8.3) at room temperature
(Fig. 3A). For GeXIVA, three major products were formed
within 20 h. The three major peaks were observed in the ultraperformance liquid chromatography trace, accounting for ⬃25,
45, and 30% of the total peptide, respectively. Analysis of each
peak using a TripleTOF 5600 mass spectrometer (AB SCIEX,
Concord, Canada) with a nanoelectrospray ionization source
revealed masses of 3450.62, 3450.62, and 3450.63 Da, respectively, each corresponding to fully oxidized GeXIVA. The three
peaks were unambiguously identified by co-elution with the
globular GeXIVA, bead GeXIVA, and ribbon GeXIVA isomers.
The HPLC peaks of ribbon and bead GeXIVA partly overlapped
and were difficult to separate (Fig. 3A, 24h). Interestingly, a
single peak representing the majority of the oxidized forms
transiently appeared from 1 to 4 h and then disappeared from 4
to 8 h (Fig. 3A, black asterisk). This transient peak partly overlaps with the major final product (Fig. 3A, 24h), which was
identified as globular GeXIVA. We hypothesized that the
globular isomer might form within 4 h and then gradually convert into other isomers. We incubated globular GeXIVA in
NH4HCO3 (pH 8.3) at room temperature at a final concentration of 20 M and the globular GeXIVA was found to be very
stable in the folding buffer for 24 h (data not shown), suggesting
that the first major peak at 4 h mainly comprises intermediate
forms with similar retention time to the globular isomer.
The one-step oxidation of reduced cGeXIVA_GG was complete at 16 h, whereas some intermediates could still be seen at
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peptides (29, 30) and is a proven strategy to improve the stability of peptides, including conotoxins (31). For example, the stability of ␣-conotoxins MII, ImI, Vc1.1, RgIA, AuIB, and -conotoxin MrIA was significantly improved through backbone
cyclization, and most of the cyclic peptides had similar or
improved activity compared with their parent peptides (32).
Most notably, Vc1.1 became orally active in animal models of
pain after backbone cyclization (33). The length and amino acid
composition of the linker used to join the N and C termini of the
parent peptide are vital factors for backbone cyclization. For
example, the length of the linker has been shown to modulate
the yields of the three isomers of framework I conotoxins (corresponding to a CC-C-C pattern) and influence their biological
activities (34 –38).
Here we investigated whether a similar strategy could be
used for ␣-conotoxin GeXIVA. We used backbone cyclization
to control the selective formation of the ribbon isomer and
investigated the effects of cyclization on structure, activity, and
stability. The ribbon isomer is formed by the oxidation of two
cysteine residues located near the N and C termini of the peptide, suggesting that backbone cyclization could be used to
direct the selective formation of the resultant disulfide bond.
The three isomers of linear GeXIVA and a suite of cyclic ribbon
GeXIVA analogs were synthesized, and their serum stabilities
and biological activities at the human ␣9␣10 (h␣9␣10) nAChR
were tested.

Cyclization improves selective folding of conotoxin GeXIVA

that time for the linear GeXIVA. Only three products were
formed, all of mass 3546.66 Da, corresponding to that of the
fully oxidized cGeXIVA_GG. The third major peak accounted
for 86% of the total peptide content and was confirmed as being
the ribbon isomer by co-elution. The two other peaks are presumably the globular and bead isomers. In contrast to linear
GeXIVA, the retention time of globular, bead, and ribbon isomers of cGeXIVA_GG separate well (Fig. 3A) as the linker
engenders ribbon cGeXIVA_GG with a larger hydrophobic
patch than ribbon GeXIVA (Fig. 3B, green), which could explain
its later retention time. Four intermediate forms were identified
over the time course. The major intermediate (Fig. 3A,
blue asterisk and labeled I1) was the most abundant of the
oxidized forms from 1 to 4 h. The major intermediate I1 of
cGeXIVA_GG was isolated, and its mass was 3548.66 Da, indicating that it has only one disulfide bond. The masses of the
three minor intermediates were each 3546.65 Da, suggesting
that they have two disulfide bonds (all labeled I2 in Fig. 3A).

310-helix (from Pro12 to Arg16; Fig. 4B). The Ser11–Pro12 peptide bond was determined to adopt a trans configuration, similar to the configuration of this bond in the ribbon and bead
isomers of linear GeXIVA (18). As shown for ribbon GeXIVA
(18), the loop formed between Cys9 and Cys20 overlays reasonably well between NMR models (RMSD of 1.38 ⫾ 0.56 Å across
backbone atoms of residues 9 –20; Table 1), although the
remainder of the peptide is somewhat disordered, suggesting a
degree of flexibility. We thus used NMR spin relaxation
measurements to characterize the backbone dynamics of
cGeXIVA_GG (Fig. 5 and Table 2). Heteronuclear T1 and
NOEs were measured and used to derive order parameters
reflective of motion of the C␣-H␣ bonds. Because of spectral
overlap, only 18 of the 30 residues could be analyzed. Nevertheless, the order parameters (0.53–0.81; mean of 0.63) suggest that
cGeXIVA_GG is moderately flexible, which agrees with the
geometric analysis of the lowest energy structures. The least
flexible region is at the C-terminal end of the Cys9 to Cys20 loop.

NMR analyses of ribbon GeXIVA and ribbon cGeXIVA_GG

Ribbon cGeXIVA_GG and ribbon GeXIVA are equipotent
inhibitors of the human ␣9␣10 nAChR subtype

A comparison of the secondary ␣H chemical shifts of ribbon
GeXIVA with those of ribbon cGeXIVA_GG suggested very
little difference in structure between the linear and cyclic analogs (Fig. 4A). The different chemical environment created by
the presence of the cyclizing linker can easily explain the minimal shift differences near the termini. Overlapping peaks in the
2D NMR spectra prevented the unambiguous assignment of
the cGeXIVA_G and cGeXIVA_GAG spin systems.
The 3D structure of cGeXIVA_GG was calculated with a
total of 171 distance restraints and found to contain a short

Linear GeXIVA isomers have been shown to selectively and
potently inhibit the rat ␣9␣10 nAChR subtype (18). Here, globular, bead, and ribbon isomers of linear GeXIVA, and cyclic
constructs of ribbon GeXIVA (cGeXIVA_G, cGeXIVA_GG,
and ribbon cGeXIVA_GAG) were tested for their functional
activity at the h␣9␣10 nAChR subtype heterologously expressed in Xenopus laevis oocytes. All three cyclic ribbon constructs tested at 100 nM inhibited ACh-evoked currents mediated by h␣9␣10 nAChRs by ⬃60 –70% (n ⫽ 4 – 6). Similarly,
J. Biol. Chem. (2017) 292(41) 17101–17112
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Figure 2. Amino acid sequences and NMR structure of ribbon GeXIVA and cyclic ribbon isomers of GeXIVA. A, amino acid sequences of ribbon GeXIVA
and cyclic analogs. The backbone cyclization of ribbon GeXIVA was carried out using different sized linkers (highlighted in red) spanning its N and C termini
(indicated by the black bracket and line). The black curved lines below the sequence show the ribbon disulfide connectivity. The ␣-carbon (C␣) RMSD of the
backbone for the parent peptide and molecular models of the cyclic peptides are shown in the last column. B, NMR solution structure of ribbon GeXIVA (green)
and models of cyclic variants (backbones in blue and linkers in red). The disulfide bonds are represented by yellow sticks, and the C␣ are shown as balls.

Cyclization improves selective folding of conotoxin GeXIVA

Downloaded from http://www.jbc.org/ at Univ of Wollongong (CAUL) on October 23, 2017

Figure 3. Time course of the oxidative folding of GeXIVA and cGeXIVA_GG. A, HPLC traces of samples taken at various times during the random folding
process. For GeXIVA, the black asterisk indicates that the peak occurring in the folding process of GeXIVA comprises intermediate forms with similar retention
time to the globular isomer, and the red asterisk indicates an impurity. The globular, bead, and ribbon GeXIVA from two-step oxidations are shown as red, green,
and blue traces, respectively. For cGeXIVA_GG, the blue asterisk indicates the major intermediate occurring in the folding process of cGeXIVA_GG. The ribbon
cGeXIVA_GG from two-step oxidation is shown as a blue trace. I1 represents the intermediate with one disulfide bond, and I2 represents the intermediates with
two disulfide bonds. B, surface representations of ribbon GeXIVA and ribbon cGeXIVA_GG. Positively charged residues are shown in blue, negative residues are
red, polar residues are white, and hydrophobic residues are green. Surface representations were created using the program PyMOL. Cyclization of ribbon
GeXIVA resulted in an additional hydrophobic patch (circle) in cGeXIVA_GG.

the bead (n ⫽ 5) and ribbon isomers (n ⫽ 8) of GeXIVA
inhibited the h␣9␣10 ACh-evoked current amplitude by
⬃60 –70%. In contrast, the globular GeXIVA was less potent,
inhibiting h␣9␣10 ACh-evoked currents by ⬃40% (n ⫽ 12)
(Fig. 6A).
The concentration-dependent activity of globular and ribbon GeXIVA, and ribbon cGeXIVA_GG at h␣9␣10 nAChRs

17104 J. Biol. Chem. (2017) 292(41) 17101–17112

were determined (Fig. 6B). All peptides reversibly inhibited
ACh-evoked currents in a concentration-dependent manner,
giving IC50 values of 198.6 ⫾ 18.9 nM (n ⫽ 4 –12) for globular
GeXIVA, 35.1 ⫾ 2.7 nM (n ⫽ 4 – 8) for ribbon GeXIVA and
37.6 ⫾ 4.9 nM (n ⫽ 4 –11) for ribbon cGeXIVA_GG. Consistent
with the previously reported potency of globular and ribbon
GeXIVA at rat ␣9␣10 nAChRs, the globular isomer of GeXIVA

Cyclization improves selective folding of conotoxin GeXIVA

(p ⬍ 0.001) at the 4-h time point, with 38% of cGeXIVA_GG
remaining (Fig. 7).

Table 1
Statistical analysis of cGeXIVA_GG structures
All statistics are given as means ⫾ S.D.
Experimental restraints
Total no. distance restraints
Intraresidue
Sequential
Medium range, i ⫺ j ⬍ 5
Long range, i ⫺ j ⱖ 5
Hydrogen bond restraints
Dihedral angle restraints
NOE violations exceeding 0.3 Å
Dihedral violations exceeding 2.0 Å
RMSD from mean structure, Å
Backbone atoms (residues 9–20)
All heavy atoms (residues 9–20)
Stereochemical qualitya
Residues in most favored Ramachandran region, %
Ramachandran outliers, %
Unfavorable side-chain rotamers, %
Clashscore, all atoms
Overall MolProbity score
a

171
90
73
8
0
2
32
0
0
1.38 ⫾ 0.56
3.33 ⫾ 0.98
77.9 ⫾ 8.9
1.4 ⫾ 1.8
3.7 ⫾ 2.6
0.1 ⫾ 0.4
1.6 ⫾ 0.3

According to MolProbity (76).

had lower potency at h␣9␣10 nAChRs than the ribbon analog.
Ribbon GeXIVA and ribbon cGeXIVA_GG had similar IC50
values, suggesting that backbone cyclization had no impact on
the potency of inhibition at h␣9␣10 nAChRs.
Serum stability of linear GeXIVA and ribbon cGeXIVA isomers
Stability assays for the ribbon isomer of GeXIVA and its three
cyclic analogs were carried out in human serum. All four peptides degraded within 2 h, but the ribbon cGeXIVA_GG
was slightly more stable than the other peptides (data for
cGeXIVA_G and GeXIVA_GAG not shown). Subsequently,
the stability of the three isomers of linear GeXIVA and of ribbon cGeXIVA_GG was compared with that of ␣-conotoxin
cVc1.1 (33) in 25% human serum. The positive control, cVc1.1,
was highly stable, whereas only ⬃20% of the three isomers of
GeXIVA remained after 4 h of incubation. Ribbon cGeXIVA_
GG was more stable than the three linear isomers of GeXIVA

Discussion
The ␣9␣10 nAChR mediates efferent olivocochlear innervations in outer hair cells and modulates immune responses in
lymphocytes (39 – 41). It is also reported to be implicated in
pain and cancer (42, 43). Only a handful of ␣-conotoxins is
currently known to selectively inhibit the ␣9␣10 nAChR (18,
44 – 46), so studies of new examples such as GeXIVA are important for defining receptor specificity. Furthermore, previous
studies have highlighted the value of backbone cyclization to
enhance the biopharmaceutical properties of ␣-conotoxins
(33, 47), and so here we attempted to apply this approach to
GeXIVA.
Molecular modeling was used to design linkers comprising
only a small number of amino acids that would introduce minimal constraints into the peptide fold. A recent study highlighted the importance of the distance between the N and C
termini in designing cyclizing linkers (48), but considering distances alone will not address limitations caused by accessible
conformations of backbones nor the orientation of the termini.
Structural perturbations may be introduced unintentionally
into a cyclic peptide when a linker is designed on the basis of
distance only, ultimately decreasing biological activity (47, 49).
In the case of ribbon GeXIVA, modeling showed that the proximity of the termini would allow cyclization with a single residue linker without affecting the structure. Because non-neutral
amino acids in the cyclizing linker sequence can have a negative
effect on biological activity (50), only Gly and Ala amino acids
were used in the linkers in the current study. These residues are
small, flexible, non-charged, and likely to have minimal interference with biological activity. No more than two sequential
Gly or Ala were used in any individual linker to avoid overlapping peaks in NMR spectra and thus avoid spectral assignment
J. Biol. Chem. (2017) 292(41) 17101–17112
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Figure 4. Structural characterization of cGeXIVA_GG. A, secondary ␣H chemical shifts of ribbon GeXIVA and ribbon cGeXIVA_GG (⌬␦H␣). The overall
secondary structures of ribbon GeXIVA and ribbon cGeXIVA_GG are similar, and both peptides display a 310-helix from Pro12 to Arg16. The black lines below the
sequence show the ribbon disulfide connectivity. B, ribbon diagram of the NMR solution structure of cGeXIVA_GG. Models were overlaid over the Cys9–Cys20
segment. Disulfide bonds are shown in yellow.

Cyclization improves selective folding of conotoxin GeXIVA
Table 2
Relaxation data, fitted parameters, and error estimates for cGeXIVA_
GG

Downloaded from http://www.jbc.org/ at Univ of Wollongong (CAUL) on October 23, 2017

Figure 5. Experimental relaxation data and derived order parameters for
cGeXIVA_GG. T1 (top panel) and heteronuclear NOE (middle panel) values for
the C␣ nuclei were measured at 600 MHz. Errors are shown as standard deviations of triplicate measurements. Only 18 of the residues could be analyzed.
A model-free analysis was used to derive order parameters (bottom panel).
Models 1 and 2 of model-free were used in the analysis. Errors, shown as
standard deviation, were estimated using a Monte Carlo algorithm.

difficulties. Linkers composed of Gly and Ala residues have
been successfully used to cyclize the ␣-conotoxins MII, RgIA,
and Vc1.1, without adversely affecting biological activity or
structure (33, 47, 49).
The linkers used in this study did not affect the activity and
structure of ribbon GeXIVA. Indeed, all cyclic ribbon variants,
i.e. cGeXIVA_G, cGeXIVA_GG, and cGeXIVA_GAG, had similar activity to the linear ribbon form at the h␣9␣10 nAChR.
Although no structural data from peptides cyclized with a G or
GAG linker were obtained because of NMR spectral overlap,
the GG linker did yield a cyclized peptide with a very similar
conformation to the linear ribbon GeXIVA. Alignment of the
lowest energy model generated from NMR data and an analysis
of the backbone relaxation measurements suggests that the
cyclic variant is most rigid in the Cys9–Cys20 loop region but
slightly more flexible in the remainder of the molecule. It has
recently been shown that backbone cyclization can enhance or
retain backbone rigidity for three different classes of peptides,
including for the conotoxin Vc1.1 (51). Cyclization appears to
have less of a rigidifying effect in GeXIVA.

17106 J. Biol. Chem. (2017) 292(41) 17101–17112

The non-directed oxidation of GeXIVA resulted in the preferential formation of the bead isomer, followed by the ribbon
and globular forms, which interestingly parallels their biological activity (18). By contrast, two previous studies employing
the one-step oxidation of ␣-conotoxins showed preferential

Cyclization improves selective folding of conotoxin GeXIVA

Figure 7. The stability of GeXIVA isomers, ribbon cGeXIVA_GG, and cVc1.1
(positive control) in 25% human serum. The one-way analysis of variance/
Tukey test and was used for comparing the remaining peptides at the 4-h
time point, and the data are expressed as the means ⫾ S.E. ***, p ⬍ 0.001. All
values (except cVc1.1) were compared with that of ribbon GeXIVA.

formation of the globular isomer under similar conditions (0.1 M
NH4HCO3, pH 8, room temperature) (52, 53). A possible
explanation for this difference in isomer formation is that
GeXIVA displays a Cys framework XIV (C-C-C-C) with 6, 10,
and 6 residues within the CysI–CysII, CysII–CysIII, and CysIII–
CysIV backbone segments, respectively, rather than the Cys
framework I (CC-C-C) of most ␣-conotoxins with 0, 4, and 3–7
residues between the cysteines.
The one-step oxidation of cGeXIVA_GG was notably different from that of the linear parent peptide because it resulted in
the preferential formation of the ribbon isomer. The use of
short cyclizing linkers has also been reported to drive oxidative
folding toward the ribbon connectivity for three other conotoxins: ␣-conotoxins ImI and AuIB and -conotoxin MrIA. Like
GeXIVA, these peptides have four Cys residues, with CysI and
CysIV being no more than three residues from the N and C
termini, respectively. A short cyclizing linker should maintain
these two Cys residues in spatial proximity in the reduced
form and favor their cross-linking by a disulfide bond during
oxidation.
During the oxidative folding of ribbon GeXIVA and ribbon cGeXIVA_GG, a major intermediate was identified. For

GeXIVA, the amount of ribbon and globular isomers plateaued
after 8 and 12 h of incubation, respectively, whereas the bead
form plateaued after 20 h. According to Wedemeyer et al. (54),
the rate of formation of disulfide bonds in an unstructured
chain decreases with the number of residues between the
two cysteines. Because 6, 10, and 6 residues exist between
successive cysteines in GeXIVA, we speculate that the major
intermediate might involve a disulfide bond between CysI
and CysII or between CysIII and CysIV and that this intermediate subsequently translates into the bead isomer. For
cGeXIVA_GG, there are only four residues between CysI and
CysIV after backbone cyclization, which may favor the formation of either a CysI–CysIV or CysII–CysIII disulfide bond
in the intermediate, thus leading to the ribbon isomer. Interestingly, three intermediates with two disulfide connectivities appeared during the course of folding of cGeXIVA_GG.
The retention times of these three intermediates were different from the three stable isomers, suggesting that the intermediates have native-like connectivities but have meta-stable conformations.
We hypothesize that the preferential formation of the ribbon
isomer probably results from the destabilization of the alternative connectivities rather than through stabilization of the ribbon form (Fig. 8). Backbone cyclization of ribbon GeXIVA possibly affects the folding energy through an entropic effect,
mainly impacting the unfolded state. Indeed, the linker has little
interaction with the rest of the peptide in molecular models,
suggesting that the termini are already maintained in proximity
in the linear form, and cyclization does not result in structural
perturbation to the core of the peptide. By contrast, the bead and
globular isomers probably adopt a different set of conformations
after being backbone cyclized because NMR characterization of
these isomers indicates that the globular form is disordered, and
the N and C termini of the bead isomer are uncoupled (18).
A two-step oxidation strategy is often used to oxidize conotoxins containing two disulfide bonds because the yields are
J. Biol. Chem. (2017) 292(41) 17101–17112
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Figure 6. Inhibition of human ␣9␣10 nAChR by linear GeXIVA and ribbon cGeXIVA isomers. A, bar graph of globular GeXIVA, bead GeXIVA, ribbon
GeXIVA, ribbon cGeXIVA_G, ribbon cGeXIVA_GG, and ribbon cGeXIVA_GAG (100 nM) inhibition of ACh-evoked peak current amplitude mediated by h␣9␣10
nAChRs. Whole-cell h␣9␣10 nAChR-mediated currents were activated by 6 M ACh. B, concentration–response curves of globular and ribbon GeXIVA and
ribbon cGeXIVA_GG inhibition of ACh-evoked currents mediated by h␣9␣10 nAChRs (means ⫾ S.E., n ⫽ 4 –12).
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typically improved compared with undirected folding (55).
However, the oxidation of GeXIVA using this strategy only produced small amounts of products, hindering high-throughput
structure-activity relationship studies and therapeutic studies.
The yield of folded ribbon GeXIVA calculated from the final
weight of oxidized peptide divided by the weight of reduced
peptide was 0.5%. Using the results of Cheneval et al. (56) to
extrapolate the yield for synthesis of an unprotected peptide,
the yield of cyclic ribbon cGeXIVA_GG through a one-step
folding method should be 8.6% using Fmoc-based solidphase peptide synthesis and considerably higher for a Bocbased approach. Additionally, the HPLC elution peaks of ribbon and bead isomers of GeXIVA overlapped, whereas
the ribbon isomer of cGeXIVA_GG is distinct, and ribbon
cGeXIVA_GG therefore can be produced in greater purity
using one-step oxidation than the ribbon GeXIVA using the
same strategy.
An alternative strategy to increase the oxidative folding yield
has been used in other cases of disulfide-rich peptides, including the widely used model system bovine pancreatic trypsin
inhibitor (BPTI). Undirected folding of this protein results in
the formation of two main species, one being native BPTI and
the other a native-like two-disulfide intermediate (57). The
addition of the N-terminal pro-region increased substantially
the native BPTI formation, and it was identified that a cysteine
residue in this region was responsible for this increased yield
(58). Tethering a cysteine residue to the C terminus with a flexible linker resulted in a similar effect, indicating that this residue acts as an internal catalyst.
Backbone cyclization typically improves the stability of disulfide-rich peptides against enzymatic degradation, as demonstrated for several conotoxins, chlorotoxin, and a spider toxin
(32, 35–38, 59, 60). However, it was recently reported that cyclization of -conotoxin PVIIA decreased its stability in human
serum (61), without significantly perturbing the structure relative to the native form (62). Here, we show that the IC50 for
cGeXIVA_GG inhibition of h␣9␣10 nAChR (37.7 ⫾ 5.0 nM) is
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Experimental procedures
Design of linkers
Linkers were designed using molecular modeling. The structure of the ribbon isomer cyclized with linkers from one to five
amino acid residues was modeled. Fifty models of the backbone
cyclized ribbon GeXIVA were generated for each of the linkers
using Modeler 6v13 (72), and the conservation of ribbon
GeXIVA native conformation was measured by computing the
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Figure 8. Schematic representation of the relative energy of the three
linear isomers of GeXIVA (black lines) and their cGeXIVA_GG (dotted red
lines) analogs. The energy difference between isomers of the same peptide
was computed using a Boltzmann distribution of the isomers at equilibrium.

comparable with that for ribbon GeXIVA (35.1 ⫾ 2.7 nM). The
stability in human serum of ribbon cGeXIVA_GG is only
slightly improved compared with linear GeXIVA, suggesting
that the main routes of degradation of GeXIVA are by endoproteases or side chain denaturation, which are typically less
affected by backbone cyclization. A possible target for such
endoproteases are the nine arginine residues in the sequence of
GeXIVA (63).
Using short linkers to enhance oxidative folding and other
biopharmaceutical properties of bioactive peptides has broader
applications than just for toxins, with perhaps a most striking
example being for insulin. Insulin is an extremely important
hormone but is difficult to synthesize because of its two chain
unique structure (64). In one study, the two peptide chains of
human insulin were fused, increasing the production yield
compared with native human proinsulin (65) while maintaining
a native-like structure (66) but with an attendant loss of biological activity (67). In a later study, Hua et al. (68) used a sixresidue linker, and the resulting insulin variant maintained biological activity and structure and also had improved folding
yield and stability. More recently, the nature of the linker region
between the two insulin chains was further investigated, resulting in the identification of an insulin variant with the highest
folding efficiency to date (64). In that study, it was shown that
the linker region had a direct effect on folding yield by enhancing the formation of the native disulfide bond connectivity. The
peptides in the current study have a direct analogy to singlechain insulin analogs: a suitable linker for cGeXIVA_GG led to
preferential formation of the ribbon isomer and significantly
improved the product yield and stability while retaining the
native-like structure and biological activity. The enhanced
pharmaceutical properties deriving from a suitable linker provide an opportunity to develop GeXIVA as a potential therapeutic for the treatment of neuropathic pain, a condition with a
huge unmet medical need (69). Treatment of neuropathic pain
is challenging, and alternative therapeutics are needed because
currently available drugs such as morphine, gabapentin, or
antidepressants are subject either to the development of tolerance or to significant side effects (70, 71).
In summary, the head-to-tail backbone cyclization via a short
linker of ribbon GeXIVA had no impact on the potency of
inhibition at h␣9␣10 nAChR and a rationally designed linker
favored the formation of the ribbon disulfide connectivity and
improved stability in human serum. The high-yield production
of ribbon cGeXIVA_GG compared with linear GeXIVA should
facilitate future in vivo studies of the analgesic potential of this
compound.
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mean C␣ root-mean-square deviation between the models and
the 20 lowest-energy NMR structures (18).
Peptide synthesis, cyclization, oxidation, and purification of
GeXIVA and variants

NMR relaxation measurements were carried out as described
previously (51). Briefly, 13C T1 (spin-lattice) relaxation times
were measured using the Bruker pulse program hsqct1etgpsi3d.2.
Spectra were acquired with a spectral width of 10 ppm over
2048 complex points in the 1H dimension and 22 ppm over
60 complex points in the 13C dimension. To determine T1
values, nine relaxation delays in the range of 0.01–1.0 s were
used. A recycle delay of 3 s was used. 13C NOEs were measured using the pulse program hsqcnoegpsi.2. Peak volumes
were measured in CCPNMR. A recycle delay of 5 s was used.
All experiments were carried out in triplicate. Order parameters were calculated by a model-free analysis using the same
protocol and target function as described previously (51),
but here the goodness-of-fit for the NOE values were given a
25% weighting compared with the T1 values to allow for the
higher uncertainty in the experimental NOE measurements.
Folding assays
Ribbon GeXIVA and cGeXIVA_GG were reduced with 10
mM dithiothreitol and isolated using RP-HPLC. Reduced peptides were dissolved in 0.1 M NH4HCO3 buffer (pH 8.3) at 20 M
and stirred at room temperature. An aliquot of peptide solution
was removed after 0, 1, 4, 8, 12, 16, 20, and 24 h and quenched
with 2% TFA. All samples were analyzed with ultra-performance liquid chromatography using a gradient 11–18% buffer
B within 28 min (increasing 1% buffer B per 4 min) in an analytical Vydac C18 column.
In vitro cRNA synthesis
Plasmid pT7TS constructs of human ␣9 and ␣10 nAChR
subunits were linearized with XbaI restriction enzymes (New
England Biolabs, Ipswich, MA) for in vitro cRNA transcription
using T7 mMessage mMachine威 transcription kits (Ambion,
Foster City, CA).
Oocyte preparation and microinjection

NMR spectroscopy
Samples of ribbon GeXIVA and its cyclic analogs were prepared by dissolving peptide (⬃1 mg) in 90% H2O, 10% D2O at a
pH of ⬃3. The spectra were recorded on a Bruker Avance III
600 MHz NMR spectrometer at 298 K and included total correlation spectroscopy (mixing time of 80 ms), NOESY (mixing time of 200 ms), and H-N and H-C heteronuclear single
quantum coherence. Chemical shifts were referenced to
internal 2, 2-dimethyl-2-silapentane-5-sulfonate at 0 ppm.
The spectra were processed with Topspin (Bruker Biospin)
and analyzed with CcpNMR analysis (version 2.4.1). Secondary ␣H chemical shifts were calculated as the difference
between the observed ␣H chemical shifts and that of the
corresponding residues in a random coil peptide (73). Structure calculations were based upon distance restraints as
derived from NOESY spectra and on backbone  and  dihedral angle restraints generated using TALOS⫹ (74). A family
of structures consistent with the experimental restraints was
calculated using CYANA (75).

Stage V–VI oocytes were obtained from X. laevis, defolliculated with 1.5 mg/ml collagenase type II (Worthington Biochemical Corp., Lakewood, NJ) at room temperature (21–
23 °C) for 1–2 h in OR-2 solution containing 82.5 mM NaCl, 2
mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4. The oocytes
were injected with 35 ng of cRNA for h␣9␣10 nAChR (concentration confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes pulled from glass capillaries
(3-000-203 GX; Drummond Scientific Co., Broomall, PA). The
oocytes were incubated at 18 °C in sterile ND96 solution composed of 96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and
5 mM HEPES, pH 7.4, supplemented with 5% fetal bovine
serum, 50 mg/liter gentamicin (Gibco) and 10,000 units/ml
penicillin-streptomycin (Gibco).
Oocyte two-electrode voltage clamp recording and data
analysis
Electrophysiological recordings were carried out 2–5 days
after cRNA microinjection. The oocytes expressing h␣9␣10
J. Biol. Chem. (2017) 292(41) 17101–17112
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The three isomers of GeXIVA and the three cyclic analogs
(cGeXIVA_G, cGeXIVA_GG and cGeXIVA_GAG) were synthesized using Fmoc-based solid-phase peptide synthesis on an
acid-sensitive resin 2-chlorotrityl chloride. Side chains of Cys
residues were protected in pairs with orthogonal protective
groups that can be removed selectively under different oxidation conditions. The acid-labile trityl group was used to protect
the side chains of Cys2 and Cys27, and the acetamidomethyl
group was used to protect Cys9 and Cys20 for the ribbon
GeXIVA and its cyclic variants. The backbone cyclization of
cyclic variants was achieved using the protocol described
recently (56). Briefly, a solution of 1% TFA in dichloromethane
(v/v) was used to cleave the linear precursor peptides of the
cyclic variants off the resin. The side chain protected precursor
peptides were dried, cyclized in O-(7-azabenzotriazol-1-yl)N,N,N⬘,N⬘-tetramethyluronium hexafluorophosphate (5 mM)
and N,N⬘-diisopropylethylamine (10 mM) in N,N-dimethylformamide for 3 h and lyophilized. The protecting group on side
chains was removed in TFA with 2% triisopropylsilane and 2%
water (v/v) for 2 h. The three isomers of GeXIVA were cleaved
and deprotected in TFA with 2% triisopropylsilane and 2%
water (v/v) for 2 h.
Two-step oxidative folding was used to form disulfide bonds:
the first disulfide bond was formed in 0.1 M ammonium bicarbonate (NH4HCO3, pH 8.3) at room temperature (21–24 °C)
for 24 h, and the second disulfide bond was formed in 0.1 M
iodine solution for 1 h. All peptides were purified by reversedphase (RP)-HPLC using Phenomenex C18 columns, and the
purification method is 15–25% buffer B within 40 min (increasing 1% buffer B per 4 min). Buffer A is 0.05% TFA in water, and
buffer B is 0.045% TFA in 90% acetonitrile.

Relaxation measurements

Cyclization improves selective folding of conotoxin GeXIVA

Stability assays
Serum stability of peptides were carried out in 25% human
serum (human male AB plasma; Sigma-Aldrich) over 4 h using
a 20 M final peptide concentration. Serum was prepared by
centrifugation at 17,000 ⫻ g for 15 min to remove the lipid
component, and the supernatant was diluted 1 in 4 in phosphate-buffered saline and incubated at 37 °C for 15 min before
the assay. Each peptide was incubated in 25% human serum at
37 °C, and aliquots were taken out at time points 0, 1, 2, 3, and
4 h, respectively. Serum proteins were denatured with 2 M urea
and precipitated with 20% TFA. All samples were centrifuged at
17,000 ⫻ g for 10 min, and the supernatant was analyzed by
analytical RP-HPLC. Remaining peptides were quantified using
peak height with absorption at 214 nm.
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